A Virtual Reality Business is testing a chronic pain therapy on a simulated patient group | Technology

A virtual reality business is testing a chronic pain therapy on a simulated patient group | Technology
 A virtual reality business is testing a chronic pain therapy on a simulated patient group 

A virtual reality business is testing a chronic pain therapy on a dummy patient group

Virtual reality company Applied VR takes an innovative approach to experimenting with new treatments for chronic pain. Instead of finding a group of people with chronic low back pain to participate in the study and avoid treatment, they pulled data from an existing database of chronic pain patients and used it as a control group. Make testing more efficient.

READ MORE: Two AI growth stocks, up 101% to 339%, according to Wall Street | Technology and Business 

AppliedVR was approved by the U.S. Food and Drug Administration in November as a virtual reality system for the treatment of chronic low back pain. Organizations are now gathering more information about how the treatment works in different groups in the real world. They are running a pilot with medical data company Komodo Health. Comodo provides customers with a vast database of anonymous patient health records covering a variety of health conditions, including chronic pain that persists in people over time.

READ MORE: Meter's latest AI discovers stronger, greener concrete formulas | Technology

Through this partnership, AppliedVR is generally able to track the experiences of people with chronic back pain and compare their experience with patients who are actively participating in trials. "What does it offer?" said Web Sun president and co-founder of Komodo Health,

READ MORE: Coding Vs Programming: What's the difference, and Which is Easier To Learn | Education 

By using real-world data as a group of patients in a study, often called a synthetic control arm, research can make research more efficient and companies can participate in more clinical trials. People don't need to register footwork. All patients who actively decided to participate in the study were given a placebo to test their treatment, not the risk of participating in the study. A synthetic control group could improve the fairness of clinical research, Sun said. Historical mistrust of minority health systems and lack of healthcare means minorities are often underestimated in clinical trials. The Commodore database contains patient race and ethnicity information, allowing research teams to join specific groups.

READ MORE: Researchers create strange magnetic particles with lasers-quantum can revolutionize computers | Technology

"This allows us to look at these different subpopulations and underestimated patient populations to see if they have different outcomes."

This method of testing design is still new. Experts are excited about the possibility, but don't use it very often. The researchers reiterated that they provide accurate results as standard controls and continue to work to determine which type of test is best for them. "Because synthetic data cannot be matched one-to-one with traditional data, the FDA remains cautious about test designs that aim to completely replace traditional data with synthetic control arms," ​​said Arnab Chatterjee, senior vice president of health products. data company. Medidata Acorn AI told PharmaVoice.

READ MORE: How to raise poultry with Virtual Reality | Technology

But institutions are becoming more accustomed to such data, especially when it is used for more traditional patient populations, Chatterjee said. Some groups have also started using synthetic patient weapons in research as part of FDA approval applications. Drug companies can use partially synthetic control arms in cancer treatment trials, the FDA said in 2020.

READ MORE: Blox Fruits Codes: Money and XP Boosts | Games and Technology

Sun said he hopes the procedure becomes more common in clinical trials. "Regulators are increasingly involved in this approach to meet all testing challenges," he said. "It saves time and money, but most importantly, it accelerates the development of high-quality therapies and provides the opportunity to bring them to market in a faster, more affordable and representative manner."

Source: Nicole Wetsman, The Verge, Direct News 99